MaxCyte Q2 revenue down 18% YoY; lowers 2025 core revenue guidance

MAXCYTE, INC.

2025-Q2 EPS reported -$0.21 vs consensus -$0.11 ▼ miss (-99.2%)

Total revenue $8.5M, down 18% YoY; core revenue up 8% to $8.2M.
Net loss $12.4M vs $9.4M loss in Q2 2024; operating expenses $21.2M.
Added two SPL clients in July (Adicet Bio, Anocca AB); total SPL agreements now 31.
Updated FY2025: core revenue flat to -10% YoY; SPL Program-related revenue ~$5M.
Expects year-end cash ≥ $155M; cites customer inventory, reprioritization headwinds.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.